|
|
Effect of neoadjuvant chemotherapy on circulating tumor cells and survival rate of locally advanced esophageal cancer |
JIANG Luquan1, ZHU Feng2, CAI Wei3, ZHENG Jian1, CHEN Jian1 |
1.Department of Thoracic Surgery, 2.Department of Clinical Laboratory, 3.Department of Oncology, Jiangsu Provincial Corps Hospital of Chinese People’s Armed Police Force,Yangzhou 225003,China |
|
|
Abstract Objective To investigate the effect of neoadjuvant chemotherapy combined with surgery on circulating tumor cells and survival rate of local advanced esophageal cancer.Methods Between June 2010 and June 2015, 110 patients with locally advanced esophageal cancer treated in our hospital were randomized into the observation group and control group. Patients in the observation group were treated with neoadjuvant chemotherapy before operation, while those in the control group were treated surgically alone. The postoperative survival rate of the two groups was compared. At the same time, immunoenrichment and immunofluorescence staining were used to identify and isolate the circulating tumor cells (CTCs) in the peripheral blood. The levels of CTCs in peripheral blood were detected before and after treatment. All patients were followed up for 3 years and the short-term survival rates of the two groups were recorded.Results There was no significant difference in the levels of CTCs between the two groups before treatment. In the first, second, and third years after treatment, the CTC values in the peripheral blood of the observation group were 6.88, 6.56 and 7.20, respectively, compared with 12.8, 13.0 and 13.2 respectively in the control group. The levels of CTCs of the observation group were significantly lower than those of the control group (P<0.05). The 1 -, 2 -, and 3 - year survival rates in the observation group were 96.36%, 89.09% and 65.45%, respectively, compared with 78.18%, 56.36% and 34.55% respectively in the control group.Conclusions Neoadjuvant chemotherapy combined with surgery can reduce the malignancy of local advanced esophageal cancer, and improve the short-term efficacy as well as the survival rate of patients.
|
Received: 20 December 2018
|
|
|
|
|
[1] |
于振涛.食管癌外科治疗现状及争议热点[J].中华肿瘤杂志,2016,38(9):646-649.
|
[2] |
Saeed N A,Mellon E A, Meredith K L,et al.Adjuvant chemotherapy and outcomes in esophageal carcinoma[J].J Gastrointest Onco, 2017,8(5):816-824.
|
[3] |
O’Neill J R ,Kennedy E D, Save V, et al. Patients unfit for neoadjuvant therapy may sill ndergo resection of locally advanced esophageal or esophagogastric junctional cance rwih acceptable oncological results[J].Int J Surg Oncol,2017,2(2): 9-11.
|
[4] |
Talmadge J E,Fidler I J.AACR centennial series:the biology of cancer metastasis:historical perspective[J].Cancer Res,2013,70(14):5649-5669.
|
[5] |
Yang J D,Campion M B,Liu M C,et al.Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma [J].Hepatology,2016,63(1):148-158.
|
[6] |
Wang H ,StoeckleinN H ,Lin P P,et al.Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion [J].Oncotarget,2016,24(6):346-351.
|
[7] |
熊 超,曾灵芝,廖立潇,等.食管癌放化疗中监测循环肿瘤细胞的临床意义[J].江西医药,2017,52 (5):5420-422.
|
[8] |
Qiao Y Y,Lin K X,Zhang Z,et al.Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma:a case report [J].World J Gastroenterol ,2015,21(25):7918-7921.
|
[9] |
明 星, 胡 蔽,谢多双,等.食管鳞癌循环肿瘤细胞在新辅助放化疗中动态变化及预后意义[J].中华肿瘤防治杂志,2017,24(8):561-565.
|
[10] |
Dasari S,Tchounwou P B.Cisplatn in cancer therapy:molecular mechanisms of action[J].Eur J Pharmacol,2014,740(5):364-378.
|
[11] |
Wang H,Stoecklein N H,Lin P P,et al. Circulating and disseminated tumor cells :diagnostic tools and therapeutic targets in motion [J].Oncotarget,2016,24(6):346-351.
|
[12] |
康宁宁,张仁泉.食管癌循环肿瘤细胞的研究进展[J]. 安徽医科大学学报,2013,48(12):1555-1558.
|
[13] |
Farsakh S,Wu T,Lalonde A,et al.High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5 [J].BMC Gas Troenterol,2017,17(1):33.
|
[14] |
张成伟,周乃康,彭碧波. 胸中、上段Ⅲ期食管癌术前同步放化疗疗效分析[J].武警医学, 2009,20(11): 976-979.
|
[1] |
LIU Feng, SUN Baolin, YU Shouqiang, QUAN Yonghui, ZHOU Zhiliang, WANG Yong, HU Mingwei, WU Kunpeng, ZHU Jun.. Survival analysis of patients with esophageal cancer[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(11): 1044-1046. |
|
|
|
|